Literature DB >> 19750059

Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Jamie Kisgen, Dana Whitney.   

Abstract

Entities:  

Keywords:  BAL 5788; BAL 9141; Ceftobiprole; RO 63-9141; cephalosporin; pyrrolidinones

Year:  2008        PMID： 19750059      PMCID： PMC2730812     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  23 in total

1.  In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.

Authors:  Andrew Walkty; Melanie Decorby; Kim Nichol; James A Karlowsky; Daryl J Hoban; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2008-04-01       Impact factor: 5.790

2.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.

Authors: 
Journal:  Drugs R D       Date:  2006

4.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  Gary J Noel; Richard S Strauss; Karen Amsler; Markus Heep; Rienk Pypstra; Joseph S Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

6.  Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.

Authors:  Pak Chan; Amanda Bishop; Thomas C Kupiec; Lawrence A Trissel; Dilip Gole; Ilias M Jimidar; Hans Vermeersch
Journal:  Am J Health Syst Pharm       Date:  2008-08-15       Impact factor: 2.637

Review 7.  Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.

Authors:  G J Noel
Journal:  Clin Microbiol Infect       Date:  2007-06       Impact factor: 8.067

Review 8.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 10.  Can beta-lactams be re-engineered to beat MRSA?

Authors:  D M Livermore
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067
View more
  7 in total

Review 1.  Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.

Authors:  B Amalakuhan; K L Echevarria; M I Restrepo
Journal:  Expert Opin Pharmacother       Date:  2017-06-21       Impact factor: 3.889

2.  In Vitro Evaluations and In Vivo Toxicity and Efficacy Studies of MFM501 against MRSA.

Authors:  Saiful Azmi Johari; Mastura Mohtar; Sharifah Aminah Syed Mohamad; Mohd Fazli Mohammat; Rohana Sahdan; Azman Mohamed; Mohamad Jemain Mohamad Ridhwan
Journal:  Biomed Res Int       Date:  2017-04-27       Impact factor: 3.411

Review 3.  Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Isaac Yin Sum Mok; Andrew Song; Drosos E Karageorgopoulos; Apostolos Armaganidis; Jeffrey Lipman; Sotirios Tsiodras
Journal:  Microorganisms       Date:  2019-08-18

Review 4.  Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics.

Authors:  Charlotte M J Wesseling; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-08-10       Impact factor: 5.578

Review 5.  New antibiotic agents in the pipeline and how they can help overcome microbial resistance.

Authors:  Ian M Gould; Abhijit M Bal
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

Review 6.  The Continuing Threat of Methicillin-Resistant Staphylococcus aureus.

Authors:  Márió Gajdács
Journal:  Antibiotics (Basel)       Date:  2019-05-02

Review 7.  Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies.

Authors:  Sandeep Nayar; Ashfaq Hasan; Pradyut Waghray; Srinivasan Ramananthan; Jaishid Ahdal; Rishi Jain
Journal:  Lung India       Date:  2019 Nov-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.